Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

NIH Has New Ethics Rules; Ripples Could Hurt Agency

Feb. 7, 2005

By Aaron Lorenzo

Xcyte's Shares Slump As FDA Seeks To Rework Trial Plans

Feb. 4, 2005

By Aaron Lorenzo

Xcyte's Shares Slump As FDA Seeks To Rework Trial Plans

Feb. 4, 2005

By Aaron Lorenzo

FDA Approves Nascobal After Manufacturing Issues Solved

Feb. 3, 2005

By Aaron Lorenzo

MEND Act Unveiled As Approach For Better Medicare Buying Power

Feb. 3, 2005

By Aaron Lorenzo

MEND Act Unveiled As Approach For Better Medicare Buying Power

Feb. 3, 2005

By Aaron Lorenzo

FDA Approves Nascobal After Manufacturing Issues Solved

Feb. 3, 2005

By Aaron Lorenzo

Manufacturing Issue Slows Down Timeline For Decision On Surfaxin

Feb. 2, 2005

By Aaron Lorenzo

Drug manufacturing issues caused investors to dump shares of Discovery Laboratories Inc., dropping the company's stock price by 22 percent Tuesday. (BioWorld Today)

Manufacturing Issue Slows Down Timeline For Decision On Surfaxin

Feb. 2, 2005

By Aaron Lorenzo

Drug manufacturing issues caused investors to dump shares of Discovery Laboratories Inc., dropping the company's stock price by 22 percent Tuesday. (BioWorld Today)

$12M Private Funding To Help CepTor Push Myodur Program

Feb. 1, 2005

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 18, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 18, 2025.
Maintenance, man: Lilly’s phase III weight trial hits goals
BioWorld
Eli Lilly and Co. took another step toward adding a way for patients to hang onto their weight loss when the firm disclosed positive top-line data from the phase...
AI drug developer Insilico to raise $292 million in Hong Kong IPO
BioWorld
Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to advance its clinical pipeline and invest...